Info

Headquartered in Geneva, Switzerland, Selexis is a leading biotechnology company dedicated to the development of innovative technologies and expert services for mammalian cell line development. Selexis offers comprehensive and rapid solutions for stable, high yield mammalian cell lines used in recombinant protein manufacturing of therapeutic drugs. The Company's unique SURE Cell Line DevelopmentSM services and technology, which includes Selexis' patented Selexis Genetic ElementsÔ, reduces traditional cell line development (e.g. DHFR) from 12 months to ~5 weeks* with an increase in expression more than 20 fold without any change in the scale-up process. The patented Selexis Genetic ElementsÔ improves the speed, yield and stability of production cell lines. Selexis Genetic ElementsÔ allows stable cell line development in ~5 weeks (after transfection to isolated cell clone). Additionally, Selexis Genetic ElementsÔ has been found to increase recombinant protein expression in mammalian cells in suspension and in serum-free more than 20 fold.